A/Prof John Ding
Honorary Clinical Associate Professor
Department of Medicine
284 Scholarly works
2 Projects
HIGHLIGHTS
2024
Research grants (ARC, NHMRC, MRFF)
Prospective Randomised Controlled Trial of Adult Patients With Perianal Fistulising Crohn\2019s Disease and Optimised Therapeutic Infliximab Levels (PROACTIVE)
2021
Research grants (ARC, NHMRC, MRFF)
A Prospective Randomised Controlled Trial of Adults With Perianal Fistulising Crohn\2019s Disease and Optimised Therapeutic Infliximab Levels: PROACTIVE Trial
2020
Journal article
Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China
DOI: 10.1016/S2468-1253(20)30121-72019
Journal article
Efficacy of Endoscopic Dilation of Gastroduodenal Crohn's Disease Strictures: A Systematic Review and Meta-Analysis of Individual Patient Data
DOI: 10.1016/j.cgh.2018.11.0482018
Journal article
Validation of the 'United Registries for Clinical Assessment and Research' [UR-CARE], a European online registry for clinical care and research in inflammatory bowel disease
DOI: 10.1093/ecco-jcc/jjy0152018
Journal article
Editorial: anti-TNF therapy and myopenia in Crohn's disease—another step towards personalised medicine. Authors’ reply
DOI: 10.1111/apt.144092017
Journal article
The body composition profile is associated with response to anti-TNF therapy in Crohn's disease and may offer an alternative dosing paradigm
DOI: 10.1111/apt.14293
RECENT SCHOLARLY WORKS
2026
Journal article
980 RANDOMISED CONTROLLED TRIAL OF CONTINUED INTRAVENOUS VERSUS SWITCHING TO SUBCUTANEOUS INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE: THE SUBCUTANEOUS INFLIXIMAB SWITCH STUDY (SISS).
DOI: 10.1016/s0016-5107(26)02347-32026
Journal article
980 RANDOMISED CONTROLLED TRIAL OF CONTINUED INTRAVENOUS VERSUS SWITCHING TO SUBCUTANEOUS INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE: THE SUBCUTANEOUS INFLIXIMAB SWITCH STUDY (SISS).
DOI: 10.1016/s0016-5085(26)02416-92026
Journal article
Letter: Steroid Tapering—Is Shorter Duration Better?
DOI: 10.1111/apt.706222026
Journal article
Defining Radiological Healing in Perianal Fistulizing Crohn’s Disease: A TOpClass Global Expert Delphi Consensus
DOI: 10.1016/j.cgh.2025.02.0092026
Journal article
Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease
DOI: 10.1111/apt.703402026
Journal article
Early Infliximab Levels and Clearance Predict Outcomes After Infliximab Rescue in Acute Severe Ulcerative Colitis: Results From PREDICT-UC
DOI: 10.1053/j.gastro.2025.07.0202025
Journal article
Infliximab-Induced Immune Thrombocytopenic Purpura in an Ulcerative Colitis Patient
DOI: 10.1159/0005459222025
Journal article
MRI assessment of body composition for prediction of therapeutic response to biologic agents in patients with Crohn’s disease
DOI: 10.1186/s13244-025-01930-w